ArticleNature communications2025
Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Longitudinal Evolution and Cellular Plasticity in Meningioma: Insights From Single-Cell Transcriptomics.Brain tumor research and treatment · 2026Review
- Optic nerve sheath meningioma exhibits neural niche-associated transcriptomic features and rare copy number variation-linked evolution.Brain pathology (Zurich, Switzerland) · 2026Article
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.Molecular brain · 2026Review
- A proteogenomic RNA processing mechanism drives sex differences in meningioma.Research square · 2026Article
- Spatially resolved single-cell analyses of human meningioma identify novel cell states influencing tumor microenvironment and progression.Nature genetics · 2026Article
- Single-cell phenotype-associated subpopulation identification via transfer foundation model and statistical ensemble learning.BMC biology · 2026Article
- Review
- Review
- Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.Frontiers in immunology · 2026Review
- Reprogramming natural killer cells in the tumor microenvironment: Challenges and therapeutic opportunities.Cytokine & growth factor reviews · 2025Review
- Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.Acta neuropathologica communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Meningioma is the most prevalent primary brain tumor with extensive intra-tumoral heterogeneity and high recurrence rates, particularly in high-grade meningiomas. Despite advancements in understanding the molecular underpinnings of meningiomas, the longitudinal evolutionary trajectory and cellular diversity of recurrent tumors remain elusive. In this study, we perform single-nuclei sequencing of matched primary and recurrent meningiomas to explore the dynamic transcriptional heterogeneity and evolutionary trajectory of meningioma tumor cells, as well as their molecular interactions with tumor-associated immune cells that shape the complex milieu of the meningioma microenvironment. Our findings reveal that both primary and recurrent meningiomas constitute diverse cellular compositions and hierarchies, where recurrent tumor cells are characterized by enrichments of cell cycle activities and proliferative kinetics. Integrative RNA velocity and latent time uncover divergent transcriptional trajectories in recurrent tumors, demonstrating multidirectional transitions with the dominance of COL6A3, which confers higher risk vulnerability and treatment resistance. Tumor microenvironment analysis further reveals enrichments of COL6A3-mediated interactions between immunosuppressive macrophages and tumor cells in recurrent meningiomas. Collectively, these results provide profound insights into the complex evolutionary process of meningiomas and suggest potential therapeutic strategies for the treatment of recurrent tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.